Rare Subtypes of Gastrointestinal Cancers
NCT04838327 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 130
Last updated 2024-08-07
Summary
A single-arm prospective observational translational study of biomarkers in patients receiving targeted treatment for rare subtypes of cancer of the Gastrointestinal Tract.
Conditions
- Cancer of Gastrointestinal Tract
Sponsors & Collaborators
-
Aarhus University Hospital
lead OTHER
Principal Investigators
-
Louise B Callesen, MD · Experimental Clinical Oncology
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2021-08-16
- Primary Completion
- 2025-04-01
- Completion
- 2026-04-01
Countries
- Denmark
Study Locations
More Related Trials
-
Open-label, Dose-finding Study to Determine Antibody Response to G17DT Treatment in Patients With Gastric Cancer.
NCT02233712 ·Status: COMPLETED ·Phase: PHASE2
-
First-Line and Neoadjuvant Immunotherapy for Gastric Cancer
NCT06727981 ·Status: RECRUITING
-
Study to Assess Tolerability and Safety and Antibody Response to G17DT in Gastric Cancer Patients
NCT02518529 ·Status: COMPLETED ·Phase: PHASE2
-
Biomarker-Integrated Umbrella, Advanced Gastric Cancer
NCT02951091 ·Status: COMPLETED ·Phase: NA
-
Predicting Biomarker of Gastric Cancer Chemotherapy Response
NCT03253107 ·Status: RECRUITING
-
Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy
NCT04993378 ·Status: UNKNOWN
-
Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer
NCT03694977 ·Status: UNKNOWN ·Phase: PHASE2
-
Feasibility of a Molecular Characterisation Approach to Treatment
NCT02112357 ·Status: UNKNOWN
-
Safety and Efficacy of G17DT Immunogen in the Treatment of Gastric and Gastroesophageal Cancer
NCT00042510 ·Status: COMPLETED ·Phase: PHASE2
-
Drug Sensitivity Screening for Gastrointestinal Cancer
NCT04298489 ·Status: UNKNOWN ·Phase: NA
-
The Effect of Immunological Heterogeneity of Tumor Microenvironment in the Prognosis of Gastric Cancer
NCT04819958 ·Status: UNKNOWN
-
Fruquintinib Combined With TAS102 for Advanced Gastric Cancer
NCT06102785 ·Status: RECRUITING
-
Microbiota and Metabolomics of Intestinal Type of Gastric Cancer
NCT06079554 ·Status: RECRUITING
-
Establishment of Precision Targeted Therapy Strategies for Advanced Gastric Cancer Based on Novel Molecular Subtyping
NCT06881017 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression
NCT02005484 ·Status: TERMINATED ·Phase: PHASE2
-
Safety and Efficacy of an Anticancer Medication Combined With Immune Cells in Subjects With Gastrointestinal Cancer
NCT03474861 ·Status: UNKNOWN ·Phase: PHASE1
-
Efficacy of Nilotinib in Adult Patients With Gastrointestinal Stromal Tumors Resistant to Imatinib and Sunitinib.
NCT01289028 ·Status: COMPLETED ·Phase: PHASE3
-
Gastric Cancer Registry for Epidemiology and Molecular Risk Factor
NCT03046745 ·Status: UNKNOWN
-
Dynamic Multiomics Evaluation of Anti-HER2 and Immunotherapy in HER2 Positive Gastric Cancer
NCT05348161 ·Status: UNKNOWN ·Phase: NA
-
To Evaluate KC1036 in the Patients with Advanced Digestive System Tumors
NCT05260385 ·Status: RECRUITING ·Phase: PHASE1/PHASE2
-
Prospective Assessment of nProfiler® 1 on Prognosis and Chemotherapy Response for Gastric Cancer
NCT04487717 ·Status: ACTIVE_NOT_RECRUITING
-
Phase 1 Dose Escalation Study of CGX1321 in Subjects With Advanced Gastrointestinal Tumors
NCT03507998 ·Status: UNKNOWN ·Phase: PHASE1
-
A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors
NCT05464875 ·Status: RECRUITING
-
Metabolomic and Lipidomic Analysis Predicts Immunotherapy-related Adverse Events in Gastric Cancer Patients
NCT06915389 ·Status: RECRUITING
-
Immune Combined Targeted and Chemotherapy in Perioperative Treatment of Locally Advanced Gastric Cancer
NCT05385900 ·Status: UNKNOWN ·Phase: NA